{ "week": "2026-W32", "label": "Week 32 \u2014 August 9\u201315, 2026", "week_start": "2026-08-09", "generated": "2026-08-10", "stats": { "total_entries": 1002, "new_this_week": 38, "compounds_represented": 6 }, "by_compound": { "psilocybin": [ { "id": "d0df2062209ea84705e3e453747dfafb780d0e8cc8ac71057507c9116753f117", "title": "Feasibility and Tolerability of Psilocybin for Phantom Limb Pain.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "anxiety", "sample_size": null, "status": "published", "date": "2026-08-07", "abstract": "Phantom limb pain (PLP) is a refractory condition defined by pain experienced in a missing limb. Psilocybin, a classical serotonergic psychedelic drug, can alleviate various treatment-resistant disorders but has scantly been investigated for chronic pain.\u2026", "outcome_summary": null, "doi": "10.1016/j.jpain.2026.106404", "url": "https://pubmed.ncbi.nlm.nih.gov/42567236/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psilocybin for chronic phantom limb pain in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "15c24718fedf4ed27bf598731fb674918349588a266b1eabf8280f8158fcdaba", "title": "Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-07", "abstract": "The interest in microdosing psychedelics continues to grow within academic and recreational contexts. However, microdosing practices have changed over time, and warrants examination of use patterns within a large, global sample of consumers.\u2026", "outcome_summary": null, "doi": "10.1016/j.drugpo.2026.105459", "url": "https://pubmed.ncbi.nlm.nih.gov/42566966/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Survey of human microdosing practices and patterns.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "3ad90dfdc9a5be72dd80fb3a097e044d4cb9c99edefd89605facd8ae0f5ff1dc", "title": "Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-07", "abstract": "Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function.\u2026", "outcome_summary": null, "doi": "10.1007/s40263-026-01326-4", "url": "https://pubmed.ncbi.nlm.nih.gov/42566154/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Phase 1 study on psilocybin's impact on motor function.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "419fe855d4c28bf84b66e718164b4da1dbb48ebfbfd7c9df517ddd91e8dbae4d", "title": "Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-06", "abstract": "Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up.\u2026", "outcome_summary": null, "doi": "10.1038/s41591-026-04541-0", "url": "https://pubmed.ncbi.nlm.nih.gov/42562964/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "4188a9705663de6a403c771a8631ecaec66096894c22f2b8a9a6bf4305c63453", "title": "Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-06", "abstract": "Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of conditions arising from altered brain development and leading to impairments in social, cognitive, emotional, and motor domains.\u2026", "outcome_summary": null, "doi": "10.1016/j.phrs.2026.108366", "url": "https://pubmed.ncbi.nlm.nih.gov/42562081/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Reviews therapeutic potential of psychedelics in neurodevelopmental disorders.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "b6b7d9ea7c026e74823c8cf0f8bd4a71757847f77d0fdc9e64dbae02e14e4c3b", "title": "Correspondence: \"Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy\".", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-06", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.jad.2026.122315", "url": "https://pubmed.ncbi.nlm.nih.gov/42562064/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Systematic review and meta-analysis of psilocybin therapy for depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "5acfd7ab4dfc3f5d9036e8d10b244e7090b6346eb975a45693d28b5e390dc168", "title": "Longitudinal neural and psychological changes following psilocybin under compassion imagery priming.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Psilocybin is a classic psychedelic known to alter subjective experience and induce lasting psychological changes, including increased cognitive flexibility and reduced rigid self-related beliefs.\u2026", "outcome_summary": null, "doi": "10.3389/fnhum.2026.1874178", "url": "https://pubmed.ncbi.nlm.nih.gov/42559191/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psilocybin for psychological changes and cognitive flexibility.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "a5a6c3469d4788b19216a00ace5179783be5a038c5d2ccb8531fd0575857a245", "title": "Role of \u03b2-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-05", "abstract": "Current research into the actions of psychedelic drugs is focused on 5-HT2A receptor-coupled signaling pathways, particularly \u03b2-arrestin2 signaling.\u2026", "outcome_summary": null, "doi": "10.1021/acschemneuro.6c00138", "url": "https://pubmed.ncbi.nlm.nih.gov/42554671/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Mechanism of action of psychedelic drugs in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "66bfd05f746e7927f92acb29f49c2cb8b7ca330709a852a169d4fe6bfff61df6", "title": "Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-04", "abstract": "Women experience a disproportionate burden of affective and stress-related disorders, with symptom variability shaped by endocrine transitions across the menstrual cycle, pregnancy, postpartum, and menopause.\u2026", "outcome_summary": null, "doi": "10.1038/s41380-026-03801-2", "url": "https://pubmed.ncbi.nlm.nih.gov/42552418/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psychedelic efficacy and tolerability in women's mental health.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "d5844614fbe75a3e93e59cafe4abe577fef525a5b31fd8b29c027be0cb1a1889", "title": "Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosis.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Psilocybin-assisted therapy is continuing to show significant positive effects for palliative cancer patients, both in reducing symptoms and improving one's sense of hope and meaning.\u2026", "outcome_summary": null, "doi": "10.3389/fpubh.2026.1767215", "url": "https://pubmed.ncbi.nlm.nih.gov/42548601/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psilocybin therapy for palliative cancer patients", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "787d8862ca8472abedb6ea2a8ec89242bdf09af829ed018168d08c5c922da048", "title": "Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-03", "abstract": "Psilocybin-assisted therapy has demonstrated rapid antidepressant effects in patients with cancer, but most trials have excluded individuals receiving active systemic anticancer treatment, limiting safety data in this population.\u2026", "outcome_summary": null, "doi": "10.1016/j.jpainsymman.2026.07.030", "url": "https://pubmed.ncbi.nlm.nih.gov/42546985/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psilocybin for depression in cancer patients, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "cd43368ef7f5d296627e29ec970290435276b3020be8ebb5761ac8d9783161ed", "title": "Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin", "compound": "psilocybin", "type": "phase_3", "institution": "U.S. Department of Veterans Affairs", "condition": "depression", "sample_size": null, "status": "recruiting", "date": "2026-08-06", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the clinical results from this PIVOT study conducted by U.S.\u2026", "outcome_summary": "A multi-site randomized controlled trial will evaluate the safety and efficacy of COMP360 psilocybin in treating treatment-resistant depression (TRD) in veterans, with or without concurrent PTSD. The primary efficacy measure is depression severity using MADRS.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Working-with-U-S--Department-of-Veterans-Affairs-for-Investigational-Study-of-Psilocybin/default.aspx", "source": "Compass Pathways", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "df8bc8ad2e432d0ad52b568e2dda3e69d2c2545b65219b1e7f23a46ccdacb7bd", "title": "COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression", "compound": "psilocybin", "type": "phase_2", "institution": "COMPASS Pathways plc", "condition": "depression", "sample_size": 233, "status": "completed", "date": "2021-11-09", "abstract": "The phase IIb study was a dose-finding study, assessing the safety and efficacy of COMP360 psilocybin therapy at three doses: 1mg, 10mg, 25mg.\u2026", "outcome_summary": "A phase IIb trial of COMP360 psilocybin therapy for treatment-resistant depression showed a statistically significant and clinically relevant reduction in depressive symptom severity after three weeks for patients receiving a 25mg dose, with rapid and durable treatment response. The 25mg dose also showed double the response and remission rates compared to the 1mg comparator dose at week 12.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2021/COMPASS-Pathways-announces-positive-topline-results-from-groundbreaking-phase-IIb-trial-of-investigational-COMP360-psilocybin-therapy-for-treatment-resistant-depression/default.aspx", "source": "Compass Pathways", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Phase IIb trial of psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "f1833da313b057a7291123704263e3b3ebc5a8e4494e1adc5c4847dc3a7b95c5", "title": "Promising results from first UK trial of psilocybin for depression", "compound": "psilocybin", "type": "phase_2", "institution": "King's College London", "condition": "depression", "sample_size": 60, "status": "published", "date": "2026-08-06", "abstract": "Back to King's College London homepage # King's College London 06 August 2026 ## Promising results from first UK trial of psilocybin for depression The first publicly-funded randomised controlled trial in the UK has found that a single dose of psilocybin, the active compound found in 'magic mushrooms', produced significant improvements in depression compared to a placebo.\u2026", "outcome_summary": "A single dose of psilocybin produced significant improvements in depression compared to a placebo, with 43-50% of the psilocybin group showing treatment response at 3-6 weeks, compared to 3% in the placebo group. Remission rates were also significantly higher in the psilocybin group.", "doi": null, "url": "https://www.kcl.ac.uk/news/promising-results-from-first-publicly-funded-uk-randomised-trial-of-psilocybin-for-depression", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psilocybin for depression in a human trial.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "845e9c0aca4913d46d81248a2d92e66e279fef11deac5b712cc9bc40bd2e713c", "title": "Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial", "compound": "psilocybin", "type": "phase_1", "institution": null, "condition": "PTSD", "sample_size": 12, "status": "completed", "date": "2026-07-30", "abstract": "Reprints and permissions ## About this article Check for updates. Verify currency and authenticity via CrossMark ### Cite this article Armstrong, S.B., Levin, A.W., Sepeda, N.D. et al.\u2026", "outcome_summary": "The trial found psilocybin-assisted therapy to be safe and feasible for veterans with severe, treatment-resistant PTSD. No serious adverse events occurred, and there was no increase in suicidal ideation. A significant reduction in PTSD symptoms was observed, with 75% of participants showing a treatment response or remission.", "doi": "s43856-026-01767-4", "url": "https://www.nature.com/articles/s43856-026-01767-4", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psilocybin for PTSD in veterans, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "0b729ea9cdf3ad7accd62584a1c27a378d76a5d1e0ba084cf4eb532cae31d5c9", "title": "Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial", "compound": "psilocybin", "type": "phase_3", "institution": "National Health Service (NHS)", "condition": "depression", "sample_size": null, "status": "completed", "date": "2026-08-06", "abstract": "Reprints and permissions ## About this article Check for updates. Verify currency and authenticity via CrossMark ### Cite this article Rucker, J.J., Mantingh, T., Kerr-Gaffney, J. et al.\u2026", "outcome_summary": "A randomized controlled trial examined the feasibility of administering psilocybin or placebo with psychological support for treatment-resistant depression. The trial included a two-arm, double-blind, randomized, placebo-controlled feasibility design with 6 weeks of follow-up.", "doi": "s41591-026-04541-0", "url": "https://www.nature.com/articles/s41591-026-04541-0", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "f6e99a259735facbdc773b13eaef17bdf49c3fcc67dfbe76bcaa448e9d9128e4", "title": "Scottsdale researchers celebrate Trump\u2019s order on psychedelic medicine", "compound": "psilocybin", "type": "news", "institution": "Scottsdale Research Institute", "condition": "PTSD", "sample_size": null, "status": "other", "date": "2026-04-21", "abstract": "Skip to content Your Life ArizonaHydrate ArizonaPool Safety 101Silver AppleSurprise SquadField Trip FridayChristmas in July # Scottsdale researchers celebrate Trump\u2019s order on psychedelic medicine Scottsdale researchers say Trump\u2019s new executive order could be a breakthrough for psychedelic medicine.\u2026", "outcome_summary": "President Trump signed an executive order to fast-track research and reviews of psychedelic medicines, including psilocybin and ibogaine, for conditions like PTSD, addiction, and depression. Scottsdale researchers are involved in clinical trials using psilocybin for PTSD in veterans and first responders and are seeking funding for an ibogaine trial for PTSD and traumatic brain injuries.", "doi": null, "url": "https://www.azfamily.com/2026/04/21/scottsdale-researchers-celebrate-trumps-order-psychedelic-medicine", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Regulatory and industry news on psychedelics for PTSD, addiction, depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } } ], "mdma": [ { "id": "4a7bbbe186dd97fc33117a7782c5566923aea97e885f940b6078796cdf3791ff", "title": "The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis.", "compound": "mdma", "type": "phase_2", "institution": null, "condition": "PTSD", "sample_size": null, "status": "published", "date": "2026-08-06", "abstract": "The potential safety and efficacy of the psychedelic 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has been researched in phase 2 and phase 3 clinical trials. We examined the occurrence and role of mystical experiences in MDMA-AT.\u2026", "outcome_summary": null, "doi": "10.1177/02698811261464502", "url": "https://pubmed.ncbi.nlm.nih.gov/42563131/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD is a core topic.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "d75ed96f502a0ab2edf791c496c2bdf33a33f72652d7389bf222f5503a1df7cc", "title": "Prevalence of Potential Contraindications and Risk Factors Relevant to MDMA-Assisted Therapy Among U.S. Veterans with Posttraumatic Stress Disorder.", "compound": "mdma", "type": "phase_2", "institution": null, "condition": "PTSD", "sample_size": null, "status": "published", "date": "2026-08-05", "abstract": "3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy has emerged as a potential strategy to treat posttraumatic stress disorder (PTSD). We conducted a national serial cross-sectional study of U.S.\u2026", "outcome_summary": null, "doi": "10.1080/02791072.2026.2710059", "url": "https://pubmed.ncbi.nlm.nih.gov/42555520/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD in US veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "7a7dd36d5cb631f17e2c69ff52d335e3cb86a1f0c57bf273c63073ed68956afa", "title": "VA launches MDMA-assisted mental health therapy trial", "compound": "mdma", "type": "phase_2", "institution": "U.S. Department of Veterans Affairs", "condition": "PTSD", "sample_size": 80, "status": "recruiting", "date": "2026-05-26", "abstract": "Psychedelic drugs are a class of substances that alter consciousness or awareness and can be organically or synthetically produced.\u2026", "outcome_summary": "The VA is launching a randomized controlled trial to evaluate the safety and efficacy of MDMA-assisted therapy for PTSD and alcohol use disorder in approximately 80 veterans. The trial will compare outcomes between those receiving MDMA-assisted therapy and those receiving psychotherapy with an active placebo.", "doi": null, "url": "https://www.legion.org/information-center/news/veterans-healthcare/2026/may/va-launches-mdma-assisted-mental-health-therapy-trial", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD and alcohol use disorder in veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "e08d5ccd4da377d6f4f311edaf7fb3f2a6efb607482748c471b7ebb9324f6263", "title": "What the VA\u2019s New MDMA-Assisted Therapy Trial Signals for Providers", "compound": "mdma", "type": "phase_3", "institution": "Department of Veterans Affairs", "condition": "PTSD", "sample_size": 80, "status": "recruiting", "date": "2026-05-28", "abstract": "Even after the FDA granted it a breakthrough designation, in 2024 MDMA was poised for full FDA approval as the first new PTSD treatment in decades, but concerns around trial design, safety and potential sexual misconduct in the trial led to its denial.\u2026", "outcome_summary": "The VA is launching a new clinical trial for MDMA-assisted therapy to treat PTSD and alcohol use disorder in veterans. The trial will enroll 80 veterans across Rhode Island and Connecticut.", "doi": null, "url": "https://bhbusiness.com/2026/05/28/what-the-vas-new-mdma-assisted-therapy-trial-signals-for-providers", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD and AUD in veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } } ], "ketamine": [ { "id": "e3ea1c35c504f90c3967c1bc245d9fadab8e8d559ef5a31844cf80c6e1fc0119", "title": "Intravenous ketamine for complex regional pain syndrome: Pain outcomes and predictors of response. A systematic review and meta\u2011analysis.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-04", "abstract": "Intravenous ketamine is used for complex regional pain syndrome (CRPS), but variable response and uncertain durability limit patient selection. This systematic review evaluated reported predictors of response to intravenous ketamine in CRPS and quantified the extent and duration of pain relief.\u2026", "outcome_summary": null, "doi": "10.1016/j.jpain.2026.106397", "url": "https://pubmed.ncbi.nlm.nih.gov/42551619/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Ketamine for chronic pain (CRPS) in a systematic review.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "aa349267292ef298fa116f55616388884ad3ac850cb9915975d2762e4c22b56e", "title": "Last resort: the ethical obligation to offer ketamine in psychiatric euthanasia and assisted suicide.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-05", "abstract": "Intravenous ketamine and intranasal esketamine have shown rapid effects in reversing suicidality and improving depressive symptoms.\u2026", "outcome_summary": null, "doi": "10.1136/jme-2025-111672", "url": "https://pubmed.ncbi.nlm.nih.gov/42557046/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Ketamine for psychiatric euthanasia and assisted suicide", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "b26297123489a973f2704e026c052174dc9147a3f2d6bbb3b785234db45e02ff", "title": "Long-Term Effectiveness of Repeated, Single-Day Intravenous Ketamine Infusions for Severe Arthritis: A Retrospective Cohort Study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-01", "abstract": "Ketamine, either adminstered as an infusion or orally as an analgesic, was considered only to be a drug for neuropathic pain. More recently it has been speculated to be efficacious for other types of pain, including nociceptive pain.\u2026", "outcome_summary": null, "doi": null, "url": "https://pubmed.ncbi.nlm.nih.gov/42550528/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Chronic pain treatment with ketamine.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "b63eebc345e9a429177f19e1c137fbe9d37985ede3d49cfe049272dca38c1451", "title": "(Es)ketamine in functional neurological disorder: a systematic review.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Functional neurological disorder (FND) is a common and disabling condition for which effective treatments remain limited. Clinical outcomes are often variable, particularly in chronic and comorbid presentations.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1872389", "url": "https://pubmed.ncbi.nlm.nih.gov/42548890/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Systematic review of (es)ketamine for functional neurological disorder.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "a2a8a66982cc438d5cb92dd9e91dd7bdee5419ed345b983f09279625964ad27a", "title": "Sustained abstinence in severe ketamine use disorder following ibogaine treatment case report.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Substance use disorders (SUD) involving ketamine, cocaine, and alcohol present significant clinical challenges, often characterized by high relapse rates and limited pharmacological options.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1846320", "url": "https://pubmed.ncbi.nlm.nih.gov/42548882/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Ibogaine treatment for ketamine use disorder", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "f8d47b02c643c3f3076092485ca1623b5bf6a8f77bcb835b5058e162984c6f6a", "title": "Structural synaptogenesis superior to functional modulation in a pruning-based recurrent network model of OCD.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "OCD", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Obsessive-compulsive disorder (OCD) is characterized by intrusive thoughts and repetitive behaviors, with incomplete response to current treatments suggesting limitations in prevailing neurotransmitter-focused models.\u2026", "outcome_summary": null, "doi": "10.3389/fncom.2026.1799705", "url": "https://pubmed.ncbi.nlm.nih.gov/42548786/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "OCD is a psychiatric indication, and the study is in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "71aec7da75959bb8a3a4da03d83de09731c55dad5b52f6dc9fe36b4a6749bfe1", "title": "A crucial cautionary note on frequently incorrect dose equivalence between ketamine and esketamine.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-03", "abstract": null, "outcome_summary": null, "doi": "10.1038/s41380-026-03807-w", "url": "https://pubmed.ncbi.nlm.nih.gov/42547800/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Dose equivalence for ketamine/esketamine in therapeutic context.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "0696c7a3700c2bf98bee4f43ec3ad7aba7b70562bceb7329d87bde4dcb036c1a", "title": "Is Ketamine for Depression Moving Too Fast on Weak Data?", "compound": "ketamine", "type": "news", "institution": "Trinity College Dublin", "condition": "depression", "sample_size": null, "status": "published", "date": "2026-05-15", "abstract": "\u201cThe Trinity study clearly demonstrated that the addition of ketamine repeated injections was no better in reducing depressive symptoms than repeated placebo injections, both added to standard antidepressant treatment.\u2026", "outcome_summary": "A study investigating racemic ketamine infusions for depression found no additional benefit compared to a psychoactive placebo when added to usual inpatient care, leading researchers to question if ketamine's efficacy for depression has been overstated.", "doi": null, "url": "https://www.medscape.com/viewarticle/ketamine-depression-moving-too-fast-weak-data-2026a1000fr0", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Investigates ketamine for depression, questioning efficacy data.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } } ], "lsd": [ { "id": "5436a31fc9213d2b741c0afea0fdce2b3b0601b8de4855a1f3be72a6fe698793", "title": "An ETH-LAD trip with unfavourable consequences: A case report.", "compound": "lsd", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-07", "abstract": "Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated.\u2026", "outcome_summary": null, "doi": "10.1002/bcp.70776", "url": "https://pubmed.ncbi.nlm.nih.gov/42568216/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Case report of an adverse event with ETH-LAD.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } } ], "dmt": [ { "id": "864bc58bfe3ed3c84a681e3d5eb6eced29da1a859f9c0386f863a329c9b862cf", "title": "Psychological change processes in alcohol use disorder: A qualitative study of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) with cognitive behavioural therapy.", "compound": "dmt", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-08-03", "abstract": "This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; BPL-003) administered alongside psychological support and manualised cognitive behavioural therapy (CBT) for relapse prevention in alcohol use disorder (AUD).\u2026", "outcome_summary": null, "doi": "10.1111/add.70555", "url": "https://pubmed.ncbi.nlm.nih.gov/42544757/", "source": "PubMed", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Qualitative study of 5-MeO-DMT for alcohol use disorder.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } } ], "other": [ { "id": "5a69ba07e6b0c61455577c937386fe6a7cf6939ce47bd260ee2454ff41f2cd3e", "title": "Join the Journey Toward Ethical Plant Medicine Facilitation: Certificate in Ceremony, Ethics, Reciprocity", "compound": "other", "type": "news", "institution": "Chacruna", "condition": "other", "sample_size": null, "status": "recruiting", "date": "2026-08-07", "abstract": "

October 22nd, 2026 \u2013 April 8th, 2027

Live Virtual Sessions take place on Thursdays at 10:30am-12pm PT/1:30pm-3pm ET

CEs Offered: TBD

Scholarship form

Ticket Prices

Tuition + in-person component*: $2000

Tuition (not including in-person component): $1800

Tuition for folks from the Global South: $700

Register at our page on Eventbrite!

Enrollment is now open for the 2026-27 Certificate in Ceremony, Ethics, & Reciprocity, an unparalleled educational program for ceremonial leaders and psychedelic facilitators seeking to deepen their knowledge and foster ethical, justice-informed practices.

What\u2019s This Program About?

This certificate is a 5-month, 60-hour journey designed for those already facilitating or assisting in ceremonies, aiming to create a safer, more equitable, and informed space for plant medicine practices.\u2026", "outcome_summary": "This is a 5-month, 60-hour educational program for those already facilitating or assisting in plant medicine ceremonies, focusing on ethical, justice-informed practices, risk reduction, and community accountability. It includes online sessions, readings, lectures, community forums, and an optional in-person gathering with attendance at the Psychedelic Culture 2027 Conference.", "doi": null, "url": "https://chacruna.net/join-the-journey-toward-ethical-plant-medicine-facilitation-certificate-in-ceremony-ethics-reciprocity/", "source": "Chacruna Institute", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Ethical facilitation of plant medicine ceremonies", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "aed3779a321f8d46a457dfbfea32d597009b58d57ad21d9dd50fbc06bce88e0f", "title": "Difficulties After a Trip: Emory Center for Psychedelics", "compound": "other", "type": "observational", "institution": "Emory University", "condition": "other", "sample_size": 608, "status": "published", "date": "2026-08-06", "abstract": "

\u201cTo fathom hell or soar angelic.\u201d That is how Humphry Osmond, the psychiatrist who gave us the word \u201cpsychedelic,\u201d summed up these compounds in a rhyme he mailed to Aldous Huxley in 1956.\u2026", "outcome_summary": "A mixed-methods study of 608 people found that difficulties persisted for more than a year in roughly a third of them, and for more than three years in a sixth. Other surveys indicate that around 2.6% of users seek medical, psychiatric, or psychological help after a difficult experience.", "doi": "10.1371/journal.pone.0293349", "url": "https://www.lucid.news/difficulties-after-a-trip-emory-center-for-psychedelics/", "source": "Lucid News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Observational study of difficult psychedelic experiences in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "d9bf67ce5cbc83a7044895936ad1b315b8d10978e2a35e7ae88d9b4c9f86938b", "title": "Psychedelic treatments are on the verge of FDA approval. Why Texas is pushing for them", "compound": "other", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-05-05", "abstract": "Skip to content Houston Public Media TV 8 | News 88.7 | Classical | The Vibe | HPM+ ### July 28, 2026 clear sky 80 \u00b0F PBS Passport UH ### Health & Science # Psychedelic treatments are on the verge of FDA approval.\u2026", "outcome_summary": "The FDA is fast-tracking several psychedelic compounds under review, with three companies receiving National Priority Vouchers. These include two psilocybin compounds for treatment-resistant depression and major depressive disorder, and methylone for post-traumatic stress disorder.", "doi": null, "url": "https://www.houstonpublicmedia.org/articles/news/health-science/2026/05/05/550958/psychedelic-treatments-are-on-the-verge-of-fda-approval-why-texas-is-pushing-for-them", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "FDA approval, psychedelic compounds for depression and PTSD.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "a4bc31df470ae1404d89ace83cccda7fdaf071e99ff87ae32cc40f59ce6ebcdd", "title": "'Major Step': New Law Would Prep VA for FDA-Approved Psychedelic Treatments", "compound": "other", "type": "regulatory", "institution": "Department of Veterans Affairs (VA)", "condition": "other", "sample_size": null, "status": "other", "date": "2026-04-03", "abstract": "Prior to her current role at Healing Breakthrough, an organization working to drive equitable access to evidence-based mental health treatments through the VA, Mercer was volunteering with Heroic Hearts Project and advocating for state-level issues.\u2026", "outcome_summary": "New bipartisan legislation would require the Department of Veterans Affairs (VA) to evaluate and implement emerging mental health treatments for veterans, including psychedelics, by establishing a dedicated Office of Novel Therapeutics.", "doi": null, "url": "https://www.military.com/daily-news/2026/04/06/major-step-new-law-would-prep-va-fda-approved-psychedelic-treatments.html", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Legislation to prep VA for psychedelic treatments for veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "3d309e5e14522192ce6b5e127a6a19f12dfe364b900e4e730809d3b26303dfa0", "title": "Trump signs order fast tracking review of psychedelics for mental health disorders", "compound": "other", "type": "regulatory", "institution": null, "condition": "other", "sample_size": null, "status": "approved", "date": "2026-04-18", "abstract": "Trump said that his order would expedite the reclassification of those drugs, and that he expects the FDA to approve them quickly. In 2024, the FDA rejected approval for MDMA to treat PTSD.\u2026", "outcome_summary": "President Trump signed an executive order to expedite the review of psychedelic drugs like psilocybin and ibogaine for mental health conditions and directed $50 million in federal funds to make them more accessible. The FDA will issue national priority vouchers to fast-track the review of these drugs.", "doi": null, "url": "https://www.npr.org/2026/04/18/nx-s1-5789859/psychedelic-treatments-mental-health", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Regulatory and policy news on psychedelics for mental health.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "13e536b71a5737dd8dec3d7bc46c792ab23c548e747739a982686b82dbd82468", "title": "What to Know About Trump\u2019s New Executive Order on Psychedelic Drugs", "compound": "other", "type": "news", "institution": "White House", "condition": "other", "sample_size": null, "status": "other", "date": "2026-04-22", "abstract": "## What does this mean for psychedelics as treatments? It has not always been easy to perform research on the medical uses of psychedelics; nor has pinning down a practical, evidence-based therapy using psychedelics.\u2026", "outcome_summary": "President Trump signed an executive order to accelerate the development of psychedelic drugs as medical treatments, calling for expedited FDA consideration and directing $50 million to research. While not changing FDA evidence requirements, it signals openness to scheduled substances for mental health conditions.", "doi": null, "url": "https://time.com/article/2026/04/21/trump-psychedelics-executive-order-what-to-know", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Executive order on psychedelic drug development for mental health.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } }, { "id": "f1ec11b3bff09c637167bce99d1e85ac53df864a7b42e506109a9e131aa68b1c", "title": "2026 Conference Insights: ASCP", "compound": "other", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-07-23", "abstract": "Ultimately, Brody\u2019s session was to provide psychiatrists with practical, evidence-informed guidance that reflects both the promise and the limitations of ketamine treatment in 2026.\u2026", "outcome_summary": null, "doi": null, "url": "https://www.psychiatrictimes.com/view/2026-conference-insights-ascp", "source": "General News", "first_seen": "2026-08-10", "relevance": { "relevant": true, "reason": "Practical guidance on ketamine treatment for psychiatrists.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-10" } } ] } }